Microsatellite Instability in Stage II and III Colorectal Cancer: Patterns and Profile

Abstract

Introduction: Around 80% of colorectal carcinoma are associated with chromosomal instability while rest of 20% are euploid, possessing defect in mismatch repair system (MMR) quintessential for surveillance and correction of errors introduced into microsatellites. The microsatellite instability (MSI) phenotype has three major clinical applications: prognosis of colorectal cancer (CRC), prediction of response to 5 fluorouracil, and irinotecan, and genetic assessment of Lynch syndrome. Materials and Methods: We analyzed all Stage II and Stage III colorectal cancer (CRC) for MSI, who presented at Army Hospital, Research and Referral, New Delhi, from January 2014 to December 2016. Although patients of Stage II CRC were taken throughout the study period, Stage III CRC was included in last 1½ years to compare the prevalence of MSI in these two subsets of patients. Results: 26.2% of Stage II and 11.3% of Stage III patients were found to be MSI-high (MSI-H) (P = 0.04). Nineteen (86%) of 22 MSI-H patients were below 30 years of age (P = 0.01). Of 22 MSI-H patients, 18 had right-sided tumors (P = 0.03) and only three patients had rectal tumors. Most common pattern of MSI-H tumors was loss of expression of MLH1 and PMS2, seen in 15 of 16 (88%) of Stage II and three of 6 (50%) of Stage III CRC (P = 0.04). Conclusion: We conclude higher prevalence of MSI-H tumors in Stage II, as compared to Stage III CRC, which was demonstrated slightly higher in our study compared to published literature. MSI-H tumors tend to occur with high frequency in younger population, with right-sided colonic tumors, histopathology characterized by mucinous subtype with high prevalence of tumor infiltrating lymphocytes. Loss of expression of two MMR proteins, namely, PMS2 and MLH1 has been identified in most of MSI-H patients of our study, of which 86% were <30 years of age. This is in contrast to observation in previous studies where loss of PMS2 and MLH1 proteins was observed in older (>70 years) patients with MSI-H tumors, and in younger patients, MSI-H status was associated with loss of MLH1, MSH2, and MSH6.

Keywords

Colorectal carcinoma - microsatellite instability - mismatch repair

Publication History

Article published online:
23 June 2021

• References

• 1 GLOBOCAN Available from: http://www.globocan.iarc.fr/factsheets/cancers/colorectal.asp. [Last accessed on 2017 Feb 16].
• 2 NCRP. Three-Year Report of the Population Based Cancer Registries – 2009-2011. National Cancer Registry Programme. Bangalore, India: Indian Council of Medical Research (ICMR); 2013
• 3 Culligan KM, Meyer-Gauen G, Lyons-Weiler J, Hays JB. Evolutionary origin, diversification and specialization of eukaryotic MutS homolog mismatch repair proteins. Nucleic Acids Res 2000; 28: 463-71
• 4 Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7: 335-46
• 5 Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57
• 6 Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M. et al. Heritable somatic methylation and inactivation of MSH2 in families with lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009; 41: 112-7
• 7 Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74
• 8 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67
• 9 Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934
• 10 Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-5
• 11 Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L. et al. Colorectal cancer: Mutations in a signalling pathway. Nature 2005; 436: 792
• 12 Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB. et al. Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 2003; 27: 563-70
• 13 Veitenhansl M, Stegner K, Hierl FX, Dieterle C, Feldmeier H, Gutt B. et al. 40th EASD annual meeting of the European association for the study of diabetes: Munich, germany, 5-9 september 2004. Diabetologia 2004; 47: A1-A464
• 14 Umar A, Boland CR, Terdiman JP, Syngal S, de la ChapelleA, Rüschoff J. et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-8
• 15 Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P. et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-60
• 16 Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10: 293-300
• 17 Poynter JN, Haile RW, Siegmund KD, Campbell PT, Figueiredo JC, Limburg P. et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009; 18: 2745-50
• 18 Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74
• 19 Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469-75
• 20 Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K. et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and cpG island methylator phenotype. Clin Cancer Res 2009; 15: 6412-20
• 21 Rodriguez R, Hansen LT, Phear G, Scorah J, Spang-Thomsen M, Cox A. et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin Cancer Res 2008; 14: 4576-83
• 22 Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA. et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63: 5209-12
• 23 Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La PlantB. et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131: 729-37